Clinical trialNCT00303797CompletedPhase 1Interventional

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

SponsorNational Cancer Institute (NCI)Enrollment50Refractory Chronic Lymphocytic LeukemiaRefractory Multiple MyelomaStage III Multiple MyelomaStage IV Chronic Lymphocytic LeukemiaUnspecified Adult Solid Tumor, Protocol Specific

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Shaji Kumar
Mayo Clinic
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic
Rochester, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

TanespimycinSorafenib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2005
Primary completion: 31 May 2010
Completion: —
Last update posted: 19 Mar 2013
Registered enrollment: 50
Registry id: NCT00303797

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.